Background: Emerging evidence suggests that long non coding RNA (lncRNA) small nucleolar RNA host gene 4 (SNHG4) has become a new insight into lipopolysaccharide (LPS)-induced microglia inflammation, its role in neonatal pneumonia (NP) remains to be largely unrevealed.

Methods: RT-qPCR was used to determine the expression of SNHG4 and METTL3 in the serum from NP patients and normal volunteers, as well as in LPS treated-WI-38 cells. The SNHG4 overexpression vector (pcDNA-SNHG4) was transfected into LPS-treated cells. CCK-8, Transwell, annexin V-FITC/PI, ELISA and Western blot assays were used to determine cell proliferation, migration, apoptosis, contents of IL-6, TNF-α, SOD and MDA, as well as the expression levels of NF-κB pathway proteins, respectively. The enrichment of SNHG4 in the METTL3 promoter region was assessed with RIP assay. mA quantitative analysis illustrated the mA level with or without SNHG4 overexpression or METTL3 silencing. Bioinformatics analysis and RIP-PCR were used to predict and validate YTHDF1-mediated mA levels on signal transducer and activator of transcription 2 (STAT2) mRNA in METTL3 inhibited cells. Then rescue experiments were performed to explore effects of SNHG4 and METTL3 or STAT2 on LPS-treated cell functions. Subsequently, in vivo functional experiments were performed to investigate the role of SNHG4 in LPS induced pneumonia in mice.

Results: SNHG4 was downregulated, and METTL3 was upregulated in NP patients and LPS-treated cells. SNHG4 overexpression facilitated cell proliferation, migration and SOD concentration, as well as inhibited cell apoptosis and production of IL-6, TNF-α and MDA, and suppressed the expression of NF-κB pathway proteins. Mechanistically, SNHG4 bound with METTL3 and downregulated METTL3 expression. Besides, total mA level was lower in the SNHG4 overexpressed or METTL3 inhibited cells. METTL3 interference reduced mA levels of STAT2 mRNA, decreased STAT2 mRNA stability and promoted STAT2 translation level. Upregulation of METTL3 or STAT2 reversed the effects of SNHG4 overexpression on LPS-treated cell functions.

Conclusions: This study reveals that SNHG4 promotes LPS induced inflammation in human lung fibroblasts and mouse lung tissues in vitro and in vivo by inhibiting METTL3-mediated mA level of STAT2 mRNA, which may provide a potential therapeutic mechanism for NP.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2021.08.008DOI Listing

Publication Analysis

Top Keywords

stat2 mrna
20
snhg4 overexpression
16
snhg4
14
mettl3
12
snhg4 mettl3
12
stat2
8
level stat2
8
cells snhg4
8
lps-treated cells
8
cell proliferation
8

Similar Publications

Clear cell renal cell carcinoma (ccRCC) is a prevalent malignant tumor of the urinary system. While tyrosine kinase inhibitors (TKIs) are currently the first-line treatments for advanced/metastatic ccRCC, patients often develop resistance after TKI therapy. Lipid metabolic reprogramming, a hallmark of tumor progression, contributes to acquired drug resistance in various malignant tumors.

View Article and Find Full Text PDF

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B.

Front Immunol

November 2024

Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Background: The varying individual responses to Pegylated interferon-α (Peg-IFNα) in patients with chronic hepatitis B (CHB) pose significant hurdles in treatment optimization, and the underlying mechanisms remain unclear.

Objective: We aimed to identify genetic polymorphisms influencing the efficacy of Peg-IFNα in patients with HBeAg-positive CHB, with the goal to predict Peg-IFNα response before treatment.

Methods: We employed an Asian Screening Array analysis involving 124 HBeAg-positive CHB patients treated with Peg-IFNα.

View Article and Find Full Text PDF
Article Synopsis
  • mRNA vaccines have proven effective against COVID-19 and hold promise for other uses, as they change the activity of certain genes in the body post-vaccination.
  • This study analyzed blood transcriptomes before and after mRNA vaccination to identify gene networks that are either upregulated or downregulated based on the response to the vaccine.
  • The research found that specific gene networks related to immune response and processes like viral defense can be targeted for improving future vaccine designs, potentially enhancing their effectiveness.
View Article and Find Full Text PDF

Growing evidence supports a role for versican as an important component of the inflammatory response, with both pro- and anti-inflammatory roles depending on the specific context of the system or disease under investigation. Our goal is to understand the regulation of macrophage-derived versican and the role it plays in innate immunity. In previous work, we showed that LPS triggers a signaling cascade involving Toll-like receptor (TLR)4, the Trif adaptor, type I interferons, and the type I interferon receptor, leading to increased versican expression by macrophages.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the role of Myxovirus resistance protein A (MxA) on the JAK/STAT signaling pathway in HepG2 cells, focusing on the localization and expression of MxA through various biochemical methods.
  • - Results showed that MxA is primarily localized in the cytoplasm, and while knocking down MxA does not impact STAT protein levels, it significantly lowers antiviral proteins PKR and OAS expression.
  • - Overexpressing MxA increases ISRE activity and boosts PKR and OAS levels, indicating that MxA promotes antiviral protein expression by enhancing the JAK/STAT pathway's activity, though this effect is blocked in HepG2.2.15 cells.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!